October 31, 1994 |
ICN Seeks Merger OK: ICN Pharmaceuticals Inc. will urge shareholders at its annual meeting Tuesday to approve an intra-company merger that would consolidate three partially owned subsidiaries. To streamline operations and create a company with $500 million in sales, the Costa Mesa company wants shareholders of SPI Pharmaceuticals Inc., Viratek Inc. and ICN Biomedicals Inc. to accept one share of ICN stock for each share of their stock.
August 3, 1994 |
ICN Pharmaceuticals in Costa Mesa said Thursday that it plans to streamline its operations by merging with its three affiliates, creating a new company with $500 million in annual sales. If shareholders and federal regulators approve the proposal, the new company, which will keep the name ICN Pharmaceuticals, would begin trading on the New York Stock Exchange this fall.
February 22, 1994 |
Bare Bones: Are you suffering from an overpowering desire to know just how human bones are formed? If so, then ICN Biomedicals, a subsidiary of ICN Pharmaceuticals Inc., has just the chemical for you. ICN Biomedicals said it is now selling tubulin, a protein that is a necessary component in cell structure and the formation of new cells. So far so good.